Relevance of CYP3A5 Expression on the Clinical Outcome of Patients With Renal Cell Carcinoma

被引:2
|
作者
Matsumoto, Jun [1 ]
Kotera, Yumi [1 ]
Watari, Shogo [2 ]
Takeuchi, Koichi [1 ]
Ueki, Hideo [2 ]
Koyama, Toshihiro [3 ]
Wada, Koichiro [2 ]
Fujiyoshi, Masachika [1 ]
Nasu, Yasutomo [2 ]
Ariyoshi, Noritaka [1 ]
机构
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Personalized Med & Prevent Healthcare Sci, Okayama, Japan
[2] Okayama Univ, Grad Sch Med Dent Pharmaceut Sci, Dept Urol, Okayama, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pharmaceut Biomed, Okayama, Japan
关键词
human; cytochrome P450 CYP3A; renal cell carcinoma treatment outcome; CYTOCHROME-P450; 3A; OVARIAN-CANCER; IDENTIFICATION; RESISTANCE; ISOFORM; LIVER; RAT;
D O I
10.21873/anticanres.15029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: This study aimed to elucidate the detailed characteristics of CYP3A5 expression and the association between CYP3A5 expression and clinical outcomes in patients with renal cell carcinoma (RCC). Patients and Methods: This study retrospectively enrolled 124 Japanese patients with RCC treated at the Okayama University Hospital. The commonest CYP3A5 gene polymorphism, CYP3A5*3, and expression levels of CYP3A5 mRNA and protein in each tissue were examined. Results: Expression of CYP3A5 mRNA and protein in RCC tissues was significantly down-regulated compared to that in adjacent normal tissues. High level of CYP3A5 mRNA expression significantly extended cancer-specific survival (p=0.004) and overall survival (p=0.002). The CYP3A5 mRNA expression level was identified as a significant independent prognostic factor for both cancer-specific survival and overall survival. Conclusion: CYP3A5 could serve as a potential marker for prognostication and treatment planning for patients with RCC.
引用
收藏
页码:2511 / 2521
页数:11
相关论文
共 50 条
  • [41] Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics
    Fröhlich, M
    Hoffmann, MM
    Burhenne, J
    Mikus, G
    Weiss, J
    Haefeli, WE
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 (04) : 443 - 444
  • [42] CYP3A5 Genotype Had No Influence on Renal Function after Renal Transplantation
    Kimpton, J. E.
    Hughes, A. J.
    MacPhee, I.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 683 - 683
  • [43] EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS DOSE AND BLOOD LEVELS IN RENAL TRANSPLANTATION IN CLINICAL PRACTICE
    Gillet, E.
    Charbonnier-Beaupel, F.
    Arzouk, N.
    Funck-Brentano, C.
    Hulot, J. S.
    Barrou, B.
    Zahr, N.
    TRANSPLANT INTERNATIONAL, 2013, 26 : 29 - 29
  • [44] Effect of CYP3A5, CYP3A5 and ABCB1 Genotypes in Tacrolimus Dose and Clinical Outcomes after Heart Transplantation
    Tavira, B.
    Diaz-Molina, B.
    Lambert, J. L.
    Bernardo, M. J.
    Moris, C.
    Alvarez, V.
    Lopez-Larrea, C.
    Coto, E.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (04): : S154 - S154
  • [45] Incidence and clinical relevance of paraneoplastic syndromes in patients with renal cell carcinoma
    Moldovan, Tudor
    Boynton, Dennis
    Kuperus, Joshua
    Parker, Jessica
    Noyes, Sabrina L.
    Brede, Christopher M.
    Tobert, Conrad M.
    Lane, Brian R.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (09) : 392.e11 - 392.e17
  • [46] Effects of atorvastatin on CYP3A4 and CYP3A5 mRNA expression in mononuclear cells and CYP3A activity in hypercholeresterolemic patients
    Willrich, Maria Alice V.
    Rodrigues, Alice C.
    Cerda, Alvaro
    Genvigir, Fabiana D. V.
    Arazi, Simone S.
    Dorea, Egidio L.
    Bernik, Marcia M. S.
    Bertolami, Marcelo C.
    Faludi, Andre
    Largura, Alvaro
    Baudhuin, Linnea M.
    Bryant, Sandra C.
    Hirata, Mario Hiroyuki
    Crespo Hirata, Rosario Dominguez
    CLINICA CHIMICA ACTA, 2013, 421 : 157 - 163
  • [47] Clinical outcome for patients with renal cell carcinoma metastases to the pancreas
    Gordon, Robin
    McClements, Jane
    Kirk, Gareth
    Taylor, Mark
    Diamond, Thomas
    McKie, Lloyd
    Jones, Claire
    BRITISH JOURNAL OF SURGERY, 2017, 104 : 33 - 33
  • [48] Expression and clinical relevance of HLA-G in human renal cell carcinoma
    Boujelbene, N.
    Zemni, I.
    Ben Yahia, H.
    Babay, W.
    Dhouioui, S.
    Ouzari, H.
    Mrad, K.
    Zidi, I.
    VIRCHOWS ARCHIV, 2021, 479 : S172 - S172
  • [49] CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on Tacrolimus dose requirements and clinical outcome after renal transplantation
    Glowacki, Francois
    Lionet, Arnaud
    Buob, David
    Labalette, Myriam
    Allorge, Delphine
    Provot, Francois
    Hazzan, Marc
    Noel, Christian
    Broly, Franck
    Cauffiez, Christelle
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (09) : 3046 - 3050
  • [50] Effect of CYP3A5, CYP3A4 and ABCB1 polymorphisms on tacrolimus exposure in renal transplantation patients
    Ajmi, M.
    Sahtout, W.
    Omezzine, A.
    Amor, D.
    Abderahmene, A.
    Azzabi, A.
    Ben-Rejeb, N.
    Achour, A.
    Bouslama, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 89 - 89